Citations

Clear

62 citation(s) found for "Madsen, Bo".

Palliative Care Initiated in the Emergency Department
Siman, Nina , Adeyemi, Oluwaseun , Yamarik, Rebecca , Investigators, PRIM-ER, Bellolio, Fernanda , Bourenane, Sorayah, Brody, Abraham A. , Cameron, Lauren , Cooper, Julie J. , Deutsch, Ashley, Elsayem, Ahmed , Fleischer-Black, Jessica, Gang, Mauren, Goett, Rebecca , Heaton, Heather A. , Hill, Jacob , Isaacs, Eric, Jubanyik, Karen , Lamba, Sangeeta , Lin, Michelle , Loprinzi-Brauer, Caitlin , Madsen, Troy , Modrek, Ada, Otero, Ronny, Ouchi, Kei , Richardson, Christopher , Richardson, Lynne D. , Schoenfeld, Elizabeth , Shreves, Ashley, Tan, Audrey , Uspal, Julie, Venkat, Arvind , Walker, Laura , Wittman, Ian, Zimny, Erin, Miller, Joseph , Heaton, Heather, Bellolio, M Fernanda , Schoenfeld, Elizabeth M , Grudzen, Corita R. , Cuthel, Allison M. , Goldfeld, Keith S. , Investigators, PRIM-ER, Abella, Benjamin S. , Chodosh, Joshua , Elie, Marie‐Carmelle , Fernandez, Rosemarie , Gang, Mauren, Genes, Nicholas , Horwitz, Leora Idit , Lawrence, Katharine , Miller, Joseph S. A. , Ryan, Matthew, Shaw, Matthew, Southerland, Lauren T.

Mayo Clinic

JAMA | January 15, 2025 | Volume: 333 | Issue: 7 | Pages: 599

10.1001/jama.2024.23696 | PMID 39813042 Get It

Importance The emergency department (ED) offers an opportunity to initiate palliative care for older adults with serious, life-limiting illness. Objective To assess the effect of a multicomponent intervention to initiate palliative care in the ED on hospital admission, subsequent health care use, and survival in older adults with serious, life-limiting illness. Design, Setting, and Participants Cluster randomized, stepped-wedge, clinical trial including patients aged 66 years or older who visited 1 of 29 EDs across the US between May 1, 2018, and December 31, 2022, had 12 months of prior Medicare enrollment, and a Gagne comorbidity score greater than 6, representing a risk of short-term mortality greater than 30%. Nursing home patients were excluded. Intervention A multicomponent intervention (the Primary Palliative Care for Emergency Medicine intervention) included (1) evidence-based multidisciplinary education; (2) simulation-based workshops on serious illness communication; (3) clinical decision support; and (4) audit and feedback for ED clinical staff. Main Outcome and Measures The primary outcome was hospital admission. The secondary outcomes included subsequent health care use and survival at 6 months. Results There were 98 922 initial ED visits during the study period (median age, 77 years [IQR, 71-84 years]; 50% were female; 13% were Black and 78% were White; and the median Gagne comorbidity score was 8 [IQR, 7-10]). The rate of hospital admission was 64.4% during the preintervention period vs 61.3% during the postintervention period (absolute difference, −3.1% [95% CI, −3.7% to −2.5%]; adjusted odds ratio [OR], 1.03 [95% CI, 0.93 to 1.14]). There was no difference in the secondary outcomes before vs after the intervention. The rate of admission to an intensive care unit was 7.8% during the preintervention period vs 6.7% during the postintervention period (adjusted OR, 0.98 [95% CI, 0.83 to 1.15]). The rate of at least 1 revisit to the ED was 34.2% during the preintervention period vs 32.2% during the postintervention period (adjusted OR, 1.00 [95% CI, 0.91 to 1.09]). The rate of hospice use was 17.7% during the preintervention period vs 17.2% during the postintervention period (adjusted OR, 1.04 [95% CI, 0.93 to 1.16]). The rate of home health use was 42.0% during the preintervention period vs 38.1% during the postintervention period (adjusted OR, 1.01 [95% CI, 0.92 to 1.10]). The rate of at least 1 hospital readmission was 41.0% during the preintervention period vs 36.6% during the postintervention period (adjusted OR, 1.01 [95% CI, 0.92 to 1.10]). The rate of death was 28.1% during the preintervention period vs 28.7% during the postintervention period (adjusted OR, 1.07 [95% CI, 0.98 to 1.18]). Conclusions and Relevance This multicomponent intervention to initiate palliative care in the ED did not have an effect on hospital admission, subsequent health care use, or short-term mortality in older adults with serious, life-limiting illness. Trial Registration ClinicalTrials.gov Identifier: NCT03424109
Association between Age and Body Mass Index in Patients with End-Stage Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States and Japan
Vaughan, Lisa E. , Madsen, Charles D. , Nishio, Saori , Suwabe, Tatsuya , Torres, Vicente E. , Harris, Peter C. , Hoshino, Junichi

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024r7z84a9x Get It

Early Renal Outcomes Following Heart Transplantation Using Organs Procured After Circulatory Death
Zhou, Joyce , Sise, Meghan E. , Drezek, Kamila , Wolfe, Stanley B. , Osho, Asishana A. , Prario, Monica N. , Rabi, S. Alireza , Michel, E., Tsao, Lana, Coglianese, Erin , Doucette, Meaghan, Newton‐Cheh, Christopher , Thomas, Sunu, Sutaria, Nilay, Schoenike, Mark, Christ, Anastasia M. , Villavicencio, Mauricio A. , Madsen, Joren C. , Pierson, Richard N. , D’Alessandro, David A. , Zhou, Joyce C , Ton, Van-Khue , Christ, Anastasia M , Paneitz, Dane C , Villavicencio, Mauricio, Madsen, Joren C , Pierson, Richard , Lewis, Gregory D , D'Alessandro, David A , Zlotoff, Daniel A , Wolfe, Stanley , Osho, Asishana , Michel, Eriberto , Ton, Van‐Khue , Lewis, Gregory D.

Mayo Clinic

Journal of the American Heart Association | October 8, 2024 | Volume: 13 | Issue: 20 | Pages: No page available

10.1161/jaha.124.035443 | PMID 39377217 Get It

Background Transplantation using hearts obtained through donation after circulatory death (DCD) is increasing, but data on recipient renal outcomes are limited. Methods and Results Patients at a single institution who underwent heart transplantation using organs procured through DCD or donation after brain death (DBD) from April 2016 to August 2022 were included in this retrospective cohort study. Hemodynamic measures were collected via right heart catheterization performed 1 week after transplantation. Posttransplantation renal outcomes included estimated glomerular filtration rate at 1 week, 4 weeks, and 16 weeks, and the incidence of acute kidney injury (AKI) and renal replacement therapy within 1 week. The analysis included 225 patients (55 recipients of DCD). Baseline characteristics were comparable between recipients of DCD and DBD. Renal outcomes within 1 week posttransplantation in recipients of DCD were similar to recipients of DBD, including percent change in estimated glomerular filtration rate (−37.9% [−58.6 to −6.2] versus −31.9% [−52.4 to −9.9]; P =0.91), incidence of AKI (47.3% versus 46.5%; P >0.99) and incidence of renal replacement therapy (3.6% versus 4.7%; P >0.99). Recipients of DCD with AKI within 1 week (“early AKI”) did not recover to baseline estimated glomerular filtration rate (75.8 [60.2–91.3] mL/min per 1.73 m 2 ) by week 16 (59.3 [46.9–73.6] mL/min per 1.73 m 2 ; P =0.002), whereas recipients without early AKI exhibited comparable estimated glomerular filtration rate to baseline by week 4 (84.5 [70.8–98.5] mL/min per 1.73 m 2 ; P =0.084). Similar trends were observed in recipients of DBD. Conclusions Recipients of DCD demonstrated similar renal outcomes compared with recipients of DBD, supporting the ongoing use of DCD transplantation. Early AKI was associated with persistent renal dysfunction for recipients of both DCD and DBD.
Characterization of Genetically Defined ARPKD-PKHD1 Patients Enriched for Childhood/Adult Onset
Jawaid, Tabinda , Chedid, Maroun , Madsen, Charles D. , El‐Youssef, Mounif, Hanna, Christian , Senum, Sarah R. , Chebib, Fouad T. , Torres, Vicente E. , Harris, Peter C.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 149-150

10.1681/asn.20223311s1149c Get It

Monoallelic COL4A3/A4/A5 Pathogenic Variants Mimicking Autosomal Dominant Polycystic Kidney Disease
Jawaid, Tabinda , Madsen, Charles D. , Senum, Sarah R. , Ali, Hamad , Torres, Vicente E. , Harris, Peter C.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 151-152

10.1681/asn.20223311s1151d Get It

Postoperative Complications After Sling Operations for Incontinence: Is Race a Factor?
Pfeuti, Courtney K. , Glasgow, Amy E. , Occhino, John A. , Madsen, Annetta, Glasgow, Amy, Madsen, Annetta M. , Habermann, Elizabeth B.

Mayo Clinic

Urogynecology | March 14, 2024 | Volume: 30 | Issue: 3 | Pages: 197-204

10.1097/spv.0000000000001451 | PMID 38484232 Get It

Importance Racial and ethnic disparities exist in urogynecologic surgery; however, literature identifying specific disparities after sling operations for stress incontinence are limited. Objective The objective of this study was to evaluate racial and ethnic disparities in surgical complications within 30 days of midurethral sling operations. Study Design This retrospective cohort study identified women who underwent an isolated midurethral sling operation between 2014 and 2021 using the American College of Surgeons National Surgical Quality Improvement Program database. Women were stratified by racial and ethnic category to assess the primary outcome, 30-day surgical complications, and the secondary outcome, comparison of urinary tract infections (UTIs). Results There were 20,066 patients included. Mean age and body mass index were 53.9 years and 30.8, respectively. More Black or African American women had diabetes and hypertension, and more American Indian or Alaska Native women used tobacco. The only difference in 30-day complications was stroke/cerebrovascular accident, which occurred in only 1 Asian, Native Hawaiian or other Pacific Islander patient (0.1%, P < 0.0001). The most frequent complication was UTI (3.3%). Black or African American women were significantly less likely to have a diagnosis of UTI than non-Hispanic White (P = 0.04), Hispanic White (P = 0.03), and American Indian or Alaska Native women (P = 0.04). Conclusions Surgical complications within 30 days of sling operations are rare. No clinically significant racial and ethnic differences in serious complications were observed. Urinary tract infection diagnoses were lower among Black or African American women than in non-Hispanic White, Hispanic White, and American Indian or Alaska Native women despite a greater comorbidity burden. No known biologic reason exists to explain lower UTI rates in this population; therefore, this finding may represent a disparity in diagnosis and treatment.
Minimally Invasive Stereotactic Laser Ablation (SLA) of Hypothalamic Hamartomas (HH) (S48.002)
Curry, Daniel J. , Cascino, Gregory, Marsh, Richard W., Viswanathan, Ashwin , Yoshor, Daniel , Takeoka, Masanori, Madsen, Joseph R. , Shetty, Anil, Wilfong, Angus A. , Worrell, Gregory A.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.s48.002 Get It

Prediction of Time-to-First Treatment (TTFT) in Favorable-Risk Chronic Lymphocytic Leukemia (CLL) Patients Using a Novel Stratification through Transcriptome Risk Scoring
Feusier, Julie , Williams, Justin A. , Jones, Brandt, Madsen, Michael J. , Camp, Nicola J. , Hu, Boyu , Avery, Brian J. , Waller, Rosalie G. , Halwani, Ahmad , Stephens, Deborah M.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 1913-1913

10.1182/blood-2023-178248 Get It

Background: CLL is the most prevalent adult leukemia with a highly heterogenous genetic landscape leading to extremely varied clinical outcomes. Previously, CLL patients with immunoglobulin heavy chain variable region ( IGHV) mutated status and presence of deletion 13q14 [del(13q)] were identified as favorable-risk with most patients remaining on lifetime observation. However, other intrinsic factors contributing to CLL disease progression and leading to treatment initiation remain unknown. Our goal was to identify patients at high-risk of progression with added predictive value (APV) beyond IGHV-status and presence of del(13q). Methods: Flow cytometry was used to sort CD19+CD5+ malignant cells in peripheral blood from CLL patients at Huntsman Cancer Institute at University of Utah and triple sequencing generated (tumor whole transcriptome and paired tumor-normal whole exome data). We used SPECTRA, a novel dimension reduction transcriptome approach, to derive a set of independent, intrinsic, quantitative transcriptome tumor variables from 249 CLL patients with quality-controlled transcriptome sequence data. From this set, 182 treatment-naïve (TN) patients with quality-controlled clinical variables were used as a discovery cohort set to derive a SPECTRA-based risk score for TTFT using multivariable Cox proportional hazards modeling. Event time was date of patient specimen acquisition to initiation of frontline therapy with patients censored at last follow-up or death. Gaussian mixture modeling (GMM) was performed to identify evidence for distinct risk groups within the quantitative risk score. GMM-risk groups, and further stratifications by IGHV mutational and del(13q) status, were used in hazard ratios (HR) and to illustrate differences in Kaplan-Meier time-to-event curves. An independent publicly available dataset of 548 TN CLL patients with clinical and transcriptome data for CD19+ enriched cells was used for replication. Results: SPECTRA produced 19 quantitative spectra variables to describe most of the expression variation across the 249 CLL patients. In multivariable Cox modeling for TTFT, 7 spectra were significant and retained in a final model, which GMM separated into a bi-modal distribution and defined high (N=83) and low-risk (N=99) groups (HR=5.7, 95% confidence interval [CI] 3.4-9.7). In a post-hoc model including IGHV mutational and del(13q) status, the spectra-risk score showed significant APV beyond both factors (p&lt;0.001 for both). The discovery study timeframe was 6.3 years (y) and included 109 IGHV-mutated and 75 del(13q) patients. In the IGHV-mutated patients, median TTFT (mTTFT) was significantly shorter for spectra-high risk patients (3.1y) vs. spectra-low risk patients (median not reached [NR]; p&lt;0.001). Similarly, in the del(13q) patients, mTTFT was significantly shorter in high-risk patients (3.3y) compared to median NR for spectra-low (p&lt;0.001) ( Figure). Importantly, stratification of patients into low- and high-risk SPECTRA scores provided significant additional information for prediction of TTFT than IGHV mutational and del(13q) status ( Figure). For validation, we applied the same spectra-risk score to the independent data set containing 301 IGHV-mutated and 278 del(13q) CLL patients. In the replication set, the mTTFT in the IGHV-mutated patients who were spectra-high was 3.3y vs. 11.2y in spectra-low (p&lt;0.001). Similarly, in the replication set of del(13q) patients, spectra-high-risk patients had a mTTFT of 2.7y vs. 10.7y for spectra-low (p&lt;0.001). Conclusion: A transcriptome risk score utilizing novel SPECTRA variables identified a substantial subset of CLL patients with IGHV-mutated status and presence of del(13q) who have uncharacteristically short TTFT, but who would be classified as favorable risk under current best practice stratification. Future directions include validating our results with external patient cohorts from Mayo Clinic and investigating the genetic and transcriptomic profile of SPECTRA low- and high-risk cohorts to determine targetable pathways for treatment.
Muc1 Modulates the Beta‐Catenin Protective Pathway During Ischemia‐Reperfusion Injury
Kinlough, Carol L., Poland, Paul A., Gendler, Sandra , Madsen, Cathy S., Singh, Sucha , Bastacky, Sheldon , Hughey, Rebecca P. , Al‐bataineh, Mohammad M. , Pastor‐Soler, Núria M. , Sutton, Timothy A. , Mang, Henry Elmer , Monga, Satdarshan P.

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.1217.5 Get It

The HIF‐1 and β‐catenin protective pathways represent the two most significant cellular responses that are activated in response to acute kidney injury. We previously reported that murine Mucin 1 (Muc1) protects kidney function and morphology in a mouse model of ischemia‐reperfusion injury (IRI) by stabilizing HIF‐1α, enhancing HIF‐1 downstream signaling and thereby preventing metabolic stress (Pastor‐Soler et al. 2015 Am. J. Physiol. Renal Physiol. 308, F1452‐F1462). We asked if Muc1 regulates the β‐catenin protective pathway during IRI as published data indicate that (i) β‐catenin is found in co‐immunoprecipitates with human MUC1 in extracts of both cultured cells and tissues, (ii) β‐catenin nuclear targeting is MUC1‐dependent in cultured human cells, and (iii) MUC1 prevents β‐catenin phosphorylation by glycogen synthase kinase 3β (GSK3b) and thereby β‐catenin degradation. Using our same mouse model of IRI, and by using immunohistochemistry and immunoblotting of kidney tissue, we found that levels of active GSK3β were significantly lower in kidneys of control mice compared to Muc1 KO mice. Consequently, β‐catenin was significantly increased at 24 and 72 h recovery and appeared in the nuclear fraction at 72 h in control mouse kidneys. Both β‐catenin induction and nuclear targeting were absent in Muc1 KO mice. In accord with these data, we also found downstream induction of β‐catenin pro‐survival factors (activated Akt, survivin, transcription factor TCF4 and its downstream target cyclin D1) and repression of pro‐apoptotic factors (p53, active Bax and cleaved caspase 3) in control mouse kidneys that were absent or aberrant in kidneys of Muc1 KO mice. Altogether, the data clearly indicate that Muc1 protection during AKI proceeds by enhancing both the HIF‐1 and β‐catenin protective pathways. Support or Funding Information This work was supported by National Institutes of Health (NIH) Grants DK‐099345 (to T. A. Sutton), DK‐084184 (to N. M. Pastor‐Soler), CA‐64389 (to S. J. Gendler), DK‐62277, DK‐100287, and DK‐095498 (to S. P. Monga), DK‐097889 (to M. M. Al‐bataineh), DK107632, DK‐079307 (Pilot Project) and Samuel and Emma Winters Foundation grant (to R. P. Hughey), and P30‐DK079307 (to the Microscopy Core N. M. Pastor‐Soler and S. Bastacky).
Invasive Multimodality Neuromonitoring to Manage Cerebral Edema in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Fainberg, Nina, Silver, Maya R. , Arena, John D. , Landzberg, Elizabeth I., Banwell, Brenda , Gambrah-Lyles, Claudia , Madsen, Peter J. , McLendon, Loren , Narula, Sona , Tucker, Alexander M. , Huh, Jimmy W. , Kienzle, Martha , McLendon, Loren A , Landzberg, Elizabeth I. , Kirschen, Matthew P.

Mayo Clinic

Critical Care Explorations | November 2, 2023 | Volume: 5 | Issue: 11 | Pages: e1003

10.1097/cce.0000000000001003 | PMID 37929184 Get It

Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory disorder of the CNS with a variety of clinical manifestations, including cerebral edema. Case Summary: A 7-year-old boy presented with headaches, nausea, and somnolence. He was found to have cerebral edema that progressed to brainstem herniation. Invasive multimodality neuromonitoring was initiated to guide management of intracranial hypertension and cerebral hypoxia while he received empiric therapies for neuroinflammation. Workup revealed serum myelin oligodendrocyte glycoprotein antibodies. He survived with a favorable neurologic outcome. Conclusion: We describe a child who presented with cerebral edema and was ultimately diagnosed with MOGAD. Much of his management was guided using data from invasive multimodality neuromonitoring. Invasive multimodality neuromonitoring may have utility in managing life-threatening cerebral edema due to neuroinflammation.